Pharma spun off from Abbott; immunology focused.
MoneyMoodBoard has not been paid to feature this listing. This review is based on publicly available information and user-submitted data. Always verify regulatory status on SEC.gov or FINRA BrokerCheck before depositing funds. MoneyMoodBoard is not a financial advisor.
This listing is unclaimed. Data was compiled by MoneyMoodBoard editors from publicly available sources and has not been confirmed by the business. Details may be incomplete or out of date — verify regulatory status before depositing money.
AbbVie (ABBV) is a pharma stock in the stocks & shares category regulated by SEC and FINRA. Founded in 2013 and headquartered in North Chicago, IL, operating for 13 years, it is most often used for building a satellite position around a core index portfolio.
Why people search for this
Find a specific company to own a slice of and decide whether the price and fundamentals make it worth holding.
AbbVie (ABBV) fits best when you are building a satellite position around a core index portfolio, and specifically when want hands-on control over individual company exposure. It also suits investors who comfortable researching companies and holding through volatility.
It is not the right pick for someone who needs guaranteed principal and a fixed coupon.
AbbVie (ABBV)'s headline cost is trading commission at $0 at most US brokers. Secondary line items include bid-ask spread (Variable, typically pennies on large caps), custody fees (None at standard brokerages). Always cross-check fees against the operator's current pricing page — schedules change without notice.
AbbVie (ABBV) is registered with or supervised by SEC (verify on SEC EDGAR), FINRA (verify on FINRA BrokerCheck), SIPC (verify on SIPC member lookup). Regulatory registration is not a guarantee against loss — it means the firm operates under a defined rule-book and is subject to enforcement when it doesn't.
The closest peer to AbbVie (ABBV) in this directory is Alphabet (GOOGL), also a mega-cap tech stock. On dividend the two differ visibly — AbbVie (ABBV) shows ~3.5% yield, while Alphabet (GOOGL) shows None. If you are torn, open both side by side in the compare tool to see every attribute laid out in one table.
| Attribute | AbbVie (ABBV) | Alphabet (GOOGL) |
|---|---|---|
| Type | Common stock | Common stock |
| Dividend | ~3.5% yield | None |
| Market | NYSE | NASDAQ |
| Sector | Healthcare | Communication services |
AbbVie (ABBV) is a pharma stock in the stocks shares category, headquartered in North Chicago, IL. Pharma spun off from Abbott; immunology focused.
AbbVie (ABBV) is a publicly traded US equity covered widely by analysts and accessible through any FINRA-registered broker. Founded in 2013, the company files quarterly and annual disclosures with the SEC, which you can review on EDGAR before taking a position. Liquidity is generally deep during US market hours.
The table below lists every fee AbbVie (ABBV) discloses in its current pricing schedule, drawn from the operator's own published pages. Compare line items against rivals in the stocks & shares compare tool before settling on a primary account.
| Trading commission | $0 at most US brokers |
|---|---|
| Bid-ask spread | Variable, typically pennies on large caps |
| Custody fees | None at standard brokerages |
This is the structured feature matrix MoneyMoodBoard editors track for every stocks & shares listing. A green check means fully supported, an orange dash means conditional on tier or geography, and a red cross means the feature is unavailable today.
These are first-party reviews submitted by verified MoneyMoodBoard readers who actually use AbbVie (ABBV). The average rating is 4.3 of five across 120 ratings, with the distribution and individual write-ups visible below for context.
4.3 / 5
Based on 120 ratings
Seed review summarising public sentiment about AbbVie (ABBV): Pharma spun off from Abbott; immunology focused. Users generally agree with the rating shown, with the trade-offs listed in the cons section being the most cited drawback.
0 people found this helpful
Before opening an account with AbbVie (ABBV), it helps to understand the category itself. The five short sections below explain how stocks & shares work, who they suit, the main risks, where they fit in a plan, and the US regulatory rules.
Stocks represent fractional ownership in a public company. Picking individual stocks gives you the most control — and the most risk — of any common investment.
A share of stock is a unit of ownership in a public company. As a shareholder you have a claim on the company's earnings and assets, can vote on certain corporate matters, and may receive dividends if the company pays them.
Investors who want hands-on control over which businesses they own, who are willing to research companies, and who can tolerate single-stock volatility.
A single company can lose most or all of its value due to competition, management mistakes, fraud, or industry decline. Concentration risk is the main reason most advisors recommend diversifying across many holdings or using funds.
Individual stocks usually sit on top of a diversified core of index funds, not in place of one. Many investors cap single-stock holdings at a fixed percentage of net worth so a blow-up in any one name can't derail the plan. Use a brokerage IRA when possible to defer or eliminate tax on gains.
Public US equities trade on SEC-registered exchanges through FINRA-member brokers. SIPC protects the securities in your account up to $500,000 if the broker fails — it does not protect against the stock itself falling. Companies must file regular disclosures on EDGAR.
Quick definitions for terms used across stocks & shares listings.
Short answers to the questions people most commonly type into search when researching AbbVie (ABBV). Each answer is composed from this listing's own data — regulator footprint, fees, headquarters, ratings — so it reflects the current state rather than a generic template.
These are the closest peers to AbbVie (ABBV) inside the stocks & shares category on MoneyMoodBoard. Open any card to compare fees, features, regulation and verified user reviews side by side, or add them to the compare tray to evaluate up to four together.
Software stock
Creative cloud and digital-document software.
Semiconductor stock
CPU and GPU designer; competitor to Intel and NVIDIA.
Mega-cap tech stock
Google search, YouTube, Android and Google Cloud parent company.
All numeric values, regulatory statuses and license details on this page reference primary sources above. Verify before depositing funds — schedules and registrations change without notice.